Thus, future studies should focus on elucidating how NLRP3 inflammasome signaling pathway factors, such as caspase-1, affect p97-mediated GluA1 trafficking after HIBD, which may benefit the development of novel HIE therapies. This evidence concerns the gene GRIA1 and perinatal asphyxia.